Presentation 7-2
*********************************
GT-111: Pre-clinical results obtained after systemic IV administration of GT-111, VBL’s lead anti-angiogenic anti-cancer drug candidate (Ad5-PPE-1(3x)-FasC) in metastatic Lewis Lung Carcinoma mice showed a near-complete destruction of the tumor vasculature leading to substantial reduction in tumor burden, and impressive results were also obtained in radio- and chemotherapy coupled studies with PPE-1(3x) targeted delivery of HSV-TK / Gancyclovir treatment in rats. VBL has also obtained proof of concept for the efficacy of GT-111 in other experimental model of cancer.
GT-211: In the mouse hindlimb ischemia model, sprouting of new blood vessel and facilitated maturation was accomplished administration of VBL’s second gene therapy product, the pro-angiogenic GT-211 (Ad5-PPE-1(3x)-VEGF-PDGF-B).Newly formed blood vessels persisted beyond 80 days from the last GT-211 administration. VBL is also exploring the potential role of PPE-1(3x) promoter as an inducer of angiogenesis in an integrative cell based systems. In conclusion, VBL has been taking advantage of its proprietary endothelial specific targeting vector to obtain proof of concept for the ability to induce on the one hand, regression of metastasis, resulting from destruction of the blood supply, and on the other hand establishment of new vasculature aiding in improved tissue perfusion. The relatively modest effects provided by current small molecules maintains VBL’s platform as an attractive, means of manipulating angiogenesis in humans in the near future.
